These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer. Kristjansdottir B; Levan K; Partheen K; Sundfeldt K Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789 [TBL] [Abstract][Full Text] [Related]
8. The O-Linked Glycome and Blood Group Antigens ABO on Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian Tumors. Vitiazeva V; Kattla JJ; Flowers SA; Lindén SK; Premaratne P; Weijdegård B; Sundfeldt K; Karlsson NG PLoS One; 2015; 10(6):e0130197. PubMed ID: 26075384 [TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer. Skírnisdóttir I; Seidal T Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012 [TBL] [Abstract][Full Text] [Related]
10. Identification and validation of salivary proteomic signatures for non-invasive detection of ovarian cancer. Tajmul M; Parween F; Singh L; Mathur SR; Sharma JB; Kumar S; Sharma DN; Yadav S Int J Biol Macromol; 2018 Mar; 108():503-514. PubMed ID: 29222021 [TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma. Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282 [TBL] [Abstract][Full Text] [Related]
12. FGF18 as a potential biomarker in serous and mucinous ovarian tumors. El-Gendi S; Abdelzaher E; Mostafa MF; Sheasha GA Tumour Biol; 2016 Mar; 37(3):3173-83. PubMed ID: 26427667 [TBL] [Abstract][Full Text] [Related]
13. Segregation of ovarian cancer stage exploiting spectral biomarkers derived from blood plasma or serum analysis: ATR-FTIR spectroscopy coupled with variable selection methods. Lima KM; Gajjar KB; Martin-Hirsch PL; Martin FL Biotechnol Prog; 2015; 31(3):832-9. PubMed ID: 25832726 [TBL] [Abstract][Full Text] [Related]
14. High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature. Hatano Y; Tamada M; Asano N; Hayasaki Y; Tomita H; Morishige KI; Hara A Diagn Pathol; 2019 Jan; 14(1):4. PubMed ID: 30636633 [TBL] [Abstract][Full Text] [Related]
16. Oviductal glycoprotein (OVGP1, MUC9): a differentiation-based mucin present in serum of women with ovarian cancer. Maines-Bandiera S; Woo MM; Borugian M; Molday LL; Hii T; Gilks B; Leung PC; Molday RS; Auersperg N Int J Gynecol Cancer; 2010 Jan; 20(1):16-22. PubMed ID: 20130498 [TBL] [Abstract][Full Text] [Related]
17. TFF3 Expression as Stratification Marker in Borderline Epithelial Tumors of the Ovary. El-Balat A; Schmeil I; Karn T; Becker S; Sänger N; Holtrich U; Arsenic R Pathol Oncol Res; 2018 Apr; 24(2):277-282. PubMed ID: 28470574 [TBL] [Abstract][Full Text] [Related]
18. THE PROGNOSTIC SIGNIFICANCE OF P53, BCL2 AND MIB1 EXPRESSIONS RELATED WITH OTHER CLINICOPATHOLOGICAL VARIABLES IN SEROUS OVARIAN CARCINOMAS. A CLINICOPATHOLOGICAL STUDY IN PERITONEAL FLUIDS. Kalogeraki A; Tamiolakis D; Matalliotaki C; Karvela-Kalogeraki I; Karvelas-Kalogerakis M; Segredakis J; Sinatkas V; Matalliotakis I Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):454-60. PubMed ID: 26204652 [TBL] [Abstract][Full Text] [Related]
19. Comparison of proteomic biomarker panels in urine and serum for ovarian cancer diagnosis. Petri AL; Simonsen AH; Høgdall E; Christensen IJ; Kjaer SK; Yip C; Risum S; Pedersen AT; Hartwell D; Fung ET; Høgdall C Proteomics Clin Appl; 2010 Mar; 4(3):304-14. PubMed ID: 21137051 [TBL] [Abstract][Full Text] [Related]